genetic predisposition of asparaginase induced hypertriglyceridemia in children with acute lymphoblastic leukemia two case reports and review of literature

Original title: “Genetic predisposition of Asparaginase-induced hypertriglyceridemia in children with acute lymphoblastic leukemia: Two case reports and review of literature.”

disseminated ganciclovir resistant cytomegalovirus in a nontransplant pediatric all patient a case report

Original title: “Disseminated Ganciclovir-Resistant Cytomegalovirus in a Nontransplant Pediatric ALL Patient: A Case Report.”

comprehensive genomic analysis of five kindreds with multiple childhood leukemias importance of individual functional analysis for rare etv6 germline variants

Original title: “Comprehensive genomic analysis of five kindreds with multiple childhood leukemias: importance of individual functional analysis for rare ETV6 germline variants.”

Emily Curran, MD, University of Cincinnati, calls for decentralized trials and stronger community-academic ties to widen ALL patient access. Although trials are essential for advancing new treatments, Curran noted that strict eligibility criteria, put in place for safety, often exclude patients with impaired kidney function, even when a treatment is not renally cleared or in prior lines of therapy. In practice, this leaves clinicians making treatment decisions for real-world patients without the benefit of trial data to guide them. Practical nuances, such as when to hold or dose-reduce a drug, rarely make it into published manuscripts. Compounding this, the pace of change in the field means that by the time findings are published, treatment approaches may have already evolved, leaving published literature outdated almost as soon as it appears. Looking ahead, Curran pointed to decentralized clinical trials as a promising solution, allowing patients to receive care locally through their own oncologists, supplemented by virtual or occasional in-person visits rather than requiring travel to a central site. Patients who enroll tend to be those willing and able to participate, and mistrust of clinical research means some communities remain · underrepresented. Geography compounds the problem: patients living hours from a trial site may be unable to commit to visits spanning multiple consecutive days, even when institutions offer support such as discounted hotel stays. Part 1: What Now Predicts Outcomes in Older Adults With ALL: Emily K. Curran, MD · Part 2: Rethinking ALL Treatment for Older Adults: Emily K. rare disease cases, helping extend expert-guided care to patients regardless of where they live.

Original title: “Clinical Trials Leave Many ALL Patients Behind: Emily K. Curran, MD | AJMC”

znf184 negatively regulates hr repair and predicts poor prognosis in acute lymphoblastic leukemia

Original title: “ZNF184 negatively regulates HR repair and predicts poor prognosis in acute lymphoblastic leukemia.”

Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment landscape of relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (B-ALL), with high remission rates across various CAR T-cell constructs. However, the durability of these responses remains a ... Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment landscape of relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (B-ALL), with high remission rates across various CAR T-cell constructs. However, the durability of these responses remains a major challenge, with many patients experiencing relapse after an initial remission. Bone Marrow Transplantation - CAR T-cell therapy in patients with acute lymphoblastic leukemia: a systematic review and meta-analysis This systematic review and meta-analysis aimed to compare the efficacy and safety of different CAR T-cell constructs across 40 clinical trials, including a total of 1540 R/R B-ALL patients. We assessed the impact of patient demographics, prior treatment exposure, and construct characteristics on treatment outcomes. The pooled complete remission rate (CRR) was 83.4% (I2 = 49%), with a minimal residual disease-negative complete remission (MRDneg-CR/CRi) rate of 92.7% (I2 = 48%). Factors associated with the clinical outcome of patients with relapsed/refractory CD19 + acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy. J Immunother Cancer. 2021;9:e003644 https://doi.org/10.1136/jitc-2021-003644. ... Myers RM, Taraseviciute A, Steinberg SM, Lamble AJ, Sheppard J, Yates B, et al. Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL.

Original title: “CAR T-cell therapy in patients with acute lymphoblastic leukemia: a systematic review and meta-analysis | Bone Marrow Transplantation”

Pharmacy Times offers the latest news and insights for the pharmacy professional and solutions that impact the everyday practice of pharmacy. The conversation begins with an overview of the current burden of ALL and limitations associated with traditional treatment approaches, setting the stage for how cellular therapies are reshaping care for patients with relapsed or refractory disease. The speakers then examine the mechanism of action and clinical trial data supporting obe-cel, highlighting how its design may influence efficacy and safety outcomes compared with earlier CAR T products. Throughout the discussion, the panel emphasizes practical considerations for pharmacists, including toxicity recognition and management, adverse event monitoring, and interdisciplinary coordination across transplant and cellular therapy teams. The episode underscores the critical role of oncology pharmacists in translating clinical trial evidence into real-world practice and supporting the safe integration of novel CAR T-cell therapies into evolving treatment paradigms for ALL. Tatyana Grgich, PharmD, BCOP, CPP, is a stem cell transplant and cell therapy pharmacist and pharmacy specialist at USC Medical Center. Jacqueline Del Pena, PharmD, is a clinical pharmacy specialist at Memorial Sloan Kettering Cancer Center, focusing on adult cell therapy services. Catie Cash, PharmD, BCOP, is a stem cell transplant and cell therapy pharmacist at Duke University Hospital. Rebecca Gonzalez, PharmD, BCOP, FASTCT, is a clinical pharmacist specialist in bone marrow transplant and cellular therapy at Moffitt Cancer Center.

Original title: “Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment | Pharmacy Times”

Real-world inotuzumab ozogamicin boosts remission in relapsed/refractory B-cell ALL, supports transplant, and flags sinusoidal obstruction syndrome risk. Reasonable remission rates were seen when inotuzumab ozogamicin was administered as a salvage therapy to patients with relapsed/refractory B-cell · acute lymphoblastic leukemia (B-ALL), with mean (SD) survival rates of 51.7% (8.1%) overall and 32.4% (8.0%) event-free, according to new research in · Blood Cancer Journal.1 These real-world data are helping to fill a data gap for such evidence currently left by limited studies in this disease and medication, which have been concentrated in clinical trial settings.2-4 Depth of response was clinically meaningful: MRD-negative status occurred in 71.4% of CR/CRi patients, enabling consolidation with ASCT or CAR T in 67.8% overall. Post-therapy hepatic SOS/veno-occlusive disease remained a major toxicity signal, with 9/10 cases after transplant and no clear correlation with cumulative dose or IO–transplant interval. European LeukemiaNet criteria. Of this group, 71.4% (n = 20) reached minimal residual disease–negative status, and 67.8% (n = 19) followed inotuzumab ozogamicin with allogeneic stem cell transplant (ASCT; n = 18) or chimeric antigen receptor (CAR) T-cell therapy (n = 1). Inotuzumab ozogamicin versus FLAG-Ida in the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia – real-world resource use data. Leuk Lymphoma. 2020;61(2):491-493. doi:10.1080/10428194.2019.1672057 · Molina O, Bataller A, Thampi N, et al. Near-haploidy and low-hypodiploidy in B-cell acute lymphoblastic leukemia: when less is too much. Cancers (Basel). 2021;14(1):32. doi:10.3390/cancers14010032 · Hepatic sinusoidal obstruction syndrome (veno-occlusive disease) in adults.

Original title: “Inotuzumab Ozogamicin Outcomes in ALL Validated Outside of Clinical Trials | AJMC”